Taselisib
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H28N8O2 |
Molar mass | 460.54 g·mol−1 |
3D model (JSmol) | |
| |
|
Taselisib (GDC-0032) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor targeting phosphoinositide 3-kinase subtype PIK3CA.[1]
Taselisib is in phase III clinical trials for treatment of metastatic breast cancer and non-small cell lung cancer.[2]
References
- ↑ "Definition of taselisib - NCI Drug Dictionary - National Cancer Institute". Cancer.gov. Retrieved 2017-01-10.
- ↑ "Clinical Trials Search Results". Cancer.gov. Retrieved 2017-01-10.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.